Fred Hutchinson Cancer Center

Fred Hutchinson Cancer Center was paid $72.70M by Medicaid between Jan 2018 and Dec 2024, across 356 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 18% of everything it billed.

33Billing provider infoFRED HUTCHINSON CANCER CENTER
SEATTLE, WA 98109

33aNPI1164493847assigned 01/30/2006

33bProvider typeGeneral Acute Care Hospital

28Total paid$72.70M

24GClaims1,480,927

24DCodes billed356

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other General Acute Care Hospital providers in Washington

Rank by total paid#6 of 49

Median peer was paid$20.06M

This provider vs. median3.6×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	189,656	$9.28M
2019	170,031	$8.11M
2020	182,853	$9.94M
2021	226,244	$12.79M
2022	272,359	$13.31M
2023	243,996	$11.14M
2024incomplete	195,788	$8.13M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J9271	Injection, pembrolizumab, 1 mg	18%	3,651	2,776	$13.00M
G0463	Hospital outpatient clinic visit for assessment and management of a patient	9.5%	102,498	62,631	$6.94M
J9299	Injection, nivolumab, 1 mg	6.1%	2,459	1,789	$4.44M
96361	Intravenous infusion, hydration; each additional hour	5.9%	18,258	6,542	$4.31M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	4.2%	33,808	18,648	$3.08M
J2505	Injection, pegfilgrastim, 6 mg	3.7%	1,906	1,376	$2.70M
J9263	Injection, oxaliplatin, 0.5 mg	3.2%	4,173	1,747	$2.33M
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	2.8%	1,955	1,106	$2.05M
J9035	Injection, bevacizumab, 10 mg	2.7%	1,724	769	$1.95M
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	2.4%	17,697	6,687	$1.71M
96415		2.1%	7,808	4,817	$1.55M
36430		2.0%	10,804	3,731	$1.44M

344 more codes

P9040	Red blood cells, leukocytes reduced, irradiated, each unit	1.7%	6,696	$1.27M
77523		1.7%	958	$1.24M
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	1.6%	5,981	$1.17M
P9037	Platelets, pheresis, leukocytes reduced, irradiated, each unit	1.6%	4,283	$1.16M
74177	Computed tomography, abdomen and pelvis; with contrast material	1.5%	8,616	$1.07M
77412		1.5%	2,902	$1.07M
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	1.2%	1,070	$900K
78815	Positron emission tomography (PET) for limited area imaging	<1%	1,418	$723K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	<1%	2,656	$589K
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	<1%	487	$581K
36592		<1%	43,249	$580K
38222		<1%	1,315	$546K
J9022	Injection, atezolizumab, 10 mg	<1%	57	$510K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	7,892	$505K
88185		<1%	4,661	$492K
J2469	Injection, palonosetron hcl, 25 mcg	<1%	10,032	$487K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	6,570	$418K
36415	Collection of venous blood by venipuncture	<1%	46,916	$411K
J1442	Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram	<1%	2,142	$407K
J9306	Injection, pertuzumab, 1 mg	<1%	250	$407K
81382		<1%	3,815	$380K
80048	Basic metabolic panel (calcium, ionized)	<1%	48,141	$371K
J0897	Injection, denosumab, 1 mg	<1%	1,278	$371K
Q5117	Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg	<1%	233	$333K
77336		<1%	3,740	$323K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	14,832	$311K
76642		<1%	4,435	$290K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	116,031	$288K
77387		<1%	6,348	$287K
80053	Comprehensive metabolic panel	<1%	49,163	$287K
87497		<1%	8,365	$282K
J0185	Injection, aprepitant, 1 mg	<1%	4,461	$275K
J9395	Injection, fulvestrant, 25 mg	<1%	1,417	$273K
36591		<1%	35,678	$262K
96367		<1%	5,293	$250K
77063	Screening digital breast tomosynthesis, bilateral	<1%	8,143	$247K
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	1,363	$244K
96416		<1%	3,220	$225K
71250		<1%	2,718	$217K
P9100	Pathogen(s) test for platelets	<1%	2,251	$208K
38220		<1%	592	$208K
80076		<1%	45,434	$202K
J9041	Injection, bortezomib, 0.1 mg	<1%	621	$189K
99214	Doctor's office visit, returning patient (more involved)	<1%	2,311	$183K
77295		<1%	329	$165K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	9,179	$155K
81268		<1%	1,810	$151K
78816		<1%	230	$147K
J1453	Injection, fosaprepitant, 1 mg	<1%	1,638	$145K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	8,200	$135K
83735		<1%	40,514	$134K
J9206	Injection, irinotecan, 20 mg	<1%	3,101	$116K
J9201	Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg	<1%	2,075	$114K
P9073	Platelets, pheresis, pathogen-reduced, each unit	<1%	426	$113K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	1,326	$108K
83615		<1%	49,149	$102K
86923		<1%	5,919	$101K
88264		<1%	2,101	$99K
88237		<1%	2,433	$98K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	<1%	245	$92K
J9070	Cyclophosphamide, 100 mg	<1%	1,122	$92K
86900		<1%	15,724	$90K
70491		<1%	1,290	$89K
88184		<1%	4,586	$85K
84100		<1%	37,744	$82K
77334		<1%	1,060	$82K
J9305	Injection, pemetrexed, not otherwise specified, 10 mg	<1%	49	$78K
C8908	Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral	<1%	356	$75K
J9312	Injection, rituximab, 10 mg	<1%	33	$75K
96375	Therapeutic injection; each additional sequential IV push	<1%	25,318	$73K
77300		<1%	902	$70K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	6,684	$70K
77065	Tomosynthesis, mammo	<1%	2,584	$67K
87799		<1%	2,489	$66K
J9358	Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	<1%	38	$65K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	2,533	$64K
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	2,360	$59K
Q3014	Telehealth originating site facility fee	<1%	2,922	$56K
96523		<1%	1,441	$55K
J1447	Injection, tbo-filgrastim, 1 microgram	<1%	269	$55K
77066	Tomosynthesis, mammo	<1%	1,971	$55K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	5,498	$54K
96402		<1%	5,523	$54K
86850		<1%	14,107	$53K
J2997	Injection, alteplase recombinant, 1 mg	<1%	1,114	$52K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	12,344	$49K
77280		<1%	399	$47K
96409		<1%	3,064	$46K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	4,805	$45K
88275		<1%	1,676	$44K
J3489	Injection, zoledronic acid, 1 mg	<1%	2,466	$44K
36593		<1%	946	$43K
J1439	Injection, ferric carboxymaltose, 1 mg	<1%	456	$42K
J9310	Injection, rituximab, 100 mg	<1%	18	$42K
71046	Radiologic examination, chest; 2 views	<1%	2,409	$41K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	<1%	2,576	$41K
77080		<1%	809	$40K
82378		<1%	10,859	$39K
81378		<1%	1,107	$39K
82533		<1%	6,094	$38K
74183		<1%	230	$38K
J1756	Injection, iron sucrose, 1 mg	<1%	2,405	$38K
78306		<1%	251	$37K
82784		<1%	5,520	$36K
99215	Doctor's office visit, returning patient (complex)	<1%	214	$35K
86830		<1%	670	$35K
86901		<1%	15,582	$34K
80069		<1%	3,293	$34K
19083		<1%	57	$34K
94010		<1%	1,908	$31K
96368		<1%	4,823	$31K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	1,114	$30K
94726		<1%	1,527	$29K
96401		<1%	4,011	$29K
36561		<1%	26	$29K
86300		<1%	4,485	$29K
88271		<1%	1,682	$29K
88341		<1%	1,101	$27K
94729		<1%	1,760	$27K
86644		<1%	2,225	$26K
81206		<1%	301	$26K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	3,419	$25K
97535	Self-care/home management training, each 15 minutes	<1%	1,515	$25K
J7050	Infusion, normal saline solution, 250 cc	<1%	24,088	$24K
86301		<1%	3,812	$23K
80197		<1%	1,947	$22K
77290		<1%	109	$22K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion	<1%	1,007	$22K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	2,536	$22K
72197		<1%	110	$21K
88342		<1%	1,897	$21K
86831		<1%	733	$21K
87040		<1%	1,377	$20K
J7030	Infusion, normal saline solution , 1000 cc	<1%	16,846	$20K
82728		<1%	8,066	$20K
99213	Doctor's office visit, returning patient (routine)	<1%	382	$20K
78812		<1%	39	$20K
96417		<1%	9,957	$19K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	<1%	59	$19K
77001		<1%	273	$19K
84443	Thyroid stimulating hormone (TSH)	<1%	10,789	$18K
80158		<1%	1,625	$18K
90686		<1%	1,571	$17K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	336	$16K
81455		<1%	69	$16K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	3,705	$16K
85730		<1%	6,755	$16K
83001		<1%	1,505	$15K
86920		<1%	2,009	$15K
J9171	Injection, docetaxel, 1 mg	<1%	72	$15K
96411		<1%	4,708	$14K
76937		<1%	255	$14K
85610		<1%	8,043	$14K
85049		<1%	5,427	$14K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	657	$13K
86704		<1%	3,347	$12K
86803		<1%	3,028	$12K
76536		<1%	188	$12K
87340		<1%	3,392	$12K
77301		<1%	29	$11K
83520		<1%	3,633	$11K
80061	Lipid panel	<1%	1,755	$11K
81267		<1%	167	$11K
86703		<1%	2,224	$11K
86999		<1%	792	$10K
87536		<1%	290	$10K
84439		<1%	7,749	$10K
81001		<1%	4,643	$10K
86334		<1%	1,716	$10K
84466		<1%	4,865	$9K
C1751	Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis)	<1%	8,017	$9K
86688		<1%	2,221	$9K
84403		<1%	1,130	$9K
87631		<1%	435	$9K
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	<1%	5,570	$9K
86592		<1%	2,243	$9K
P9033	Platelets, leukocytes reduced, irradiated, each unit	<1%	84	$8K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	133	$8K
A9579	Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml	<1%	4,729	$8K
77338		<1%	42	$8K
A6209	Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing	<1%	15,948	$8K
82105		<1%	1,555	$7K
85046		<1%	6,737	$7K
88240		<1%	2,136	$7K
86687		<1%	2,214	$7K
84550		<1%	6,021	$7K
83521		<1%	3,603	$7K
88311		<1%	1,417	$7K
J3475	Injection, magnesium sulfate, per 500 mg	<1%	9,194	$7K
84165		<1%	3,863	$7K
84153		<1%	2,404	$7K
J9145	Injection, daratumumab, 10 mg	<1%	16	$7K
83540		<1%	4,938	$7K
82670		<1%	597	$6K
82248		<1%	3,261	$6K
99195		<1%	260	$6K
88313		<1%	481	$6K
85027		<1%	2,955	$5K
J1950	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	<1%	13	$5K
J9370	Vincristine sulfate, 1 mg	<1%	1,052	$5K
82977		<1%	2,363	$5K
Q5101	Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram	<1%	35	$5K
G0008	Administration of influenza virus vaccine	<1%	2,092	$5K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	2,603	$5K
86304		<1%	1,626	$5K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	1,669	$4K
82607		<1%	1,658	$4K
84270		<1%	611	$4K
86360		<1%	251	$4K
J3480	Injection, potassium chloride, per 2 meq	<1%	3,678	$4K
82570		<1%	1,732	$4K
86922		<1%	164	$4K
87081		<1%	38	$3K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	10,757	$3K
96376		<1%	1,816	$3K
86695		<1%	374	$3K
86355		<1%	193	$3K
86359		<1%	242	$3K
78472		<1%	16	$3K
82465		<1%	1,503	$3K
J9267	Injection, paclitaxel, 1 mg	<1%	3,393	$3K
91320		<1%	203	$3K
84432		<1%	311	$3K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	2,547	$3K
99001		<1%	263	$2K
84703		<1%	899	$2K
87086	Culture, bacterial; quantitative colony count, urine	<1%	1,347	$2K
87517		<1%	168	$2K
84478		<1%	1,850	$2K
82746		<1%	1,220	$2K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	181	$2K
73720		<1%	14	$2K
97162		<1%	45	$2K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	93	$2K
J9000	Injection, doxorubicin hydrochloride, 10 mg	<1%	1,109	$2K
J0640	Injection, leucovorin calcium, per 50 mg	<1%	5,238	$2K
86140		<1%	1,378	$2K
82043		<1%	460	$2K
86800		<1%	328	$2K
J9190	Injection, fluorouracil, 500 mg	<1%	6,511	$2K
86696		<1%	383	$2K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	<1%	28	$2K
77332		<1%	25	$2K
86317		<1%	150	$2K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,358	$2K
85525		<1%	267	$2K
72156		<1%	13	$2K
70355		<1%	65	$2K
84156		<1%	799	$2K
J7060	5% dextrose/water (500 ml = 1 unit)	<1%	7,465	$1K
86787		<1%	425	$1K
83002		<1%	173	$1K
J3490	Unclassified drugs	<1%	1,230	$1K
86141		<1%	819	$1K
83690		<1%	1,910	$1K
A4648	Tissue marker, implantable, any type, each	<1%	855	$1K
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	980	$1K
80195		<1%	182	$1K
86965		<1%	88	$1K
76942		<1%	19	$1K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	318	$1K
84702		<1%	307	$1K
90480		<1%	203	$1K
82150		<1%	1,657	$1K
86382		<1%	116	$1K
82565		<1%	678	$1K
87522	Neg quan hep c or qual rna	<1%	63	$999.62
90662		<1%	452	$973.08
83010		<1%	229	$956.94
82232		<1%	98	$955.48
86706		<1%	766	$907.38
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	262	$888.13
83021		<1%	101	$863.43
90656		<1%	94	$774.06
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	59	$739.98
87390		<1%	116	$714.37
87205		<1%	549	$705.24
85651		<1%	726	$598.16
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	8,575	$563.05
83721		<1%	474	$560.90
J9045	Injection, carboplatin, 50 mg	<1%	1,753	$543.14
83880		<1%	81	$503.55
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	241	$488.30
86778		<1%	41	$378.66
90670		<1%	26	$355.34
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	<1%	77	$306.02
85384		<1%	343	$279.84
90739		<1%	14	$276.69
J0461	Injection, atropine sulfate, 0.01 mg	<1%	2,406	$275.93
82550		<1%	196	$269.22
90472	Immunization administration, each additional vaccine (list separately)	<1%	108	$268.39
86902		<1%	65	$263.51
86480		<1%	28	$262.28
83718		<1%	269	$240.91
96377		<1%	90	$236.22
84484		<1%	100	$224.80
86481		<1%	16	$223.18
94760		<1%	139	$219.10
A9560	Technetium tc-99m labeled red blood cells, diagnostic, per study dose, up to 30 millicuries	<1%	16	$213.18
J1170	Injection, hydromorphone, up to 4 mg	<1%	728	$212.49
81479	Unlisted molecular pathology procedure	<1%	15	$177.72
80299		<1%	21	$171.56
85379		<1%	32	$160.67
86777		<1%	28	$154.33
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	12	$135.42
86880		<1%	61	$123.79
87103		<1%	24	$123.11
88142		<1%	12	$111.19
86316		<1%	43	$102.96
J0780	Injection, prochlorperazine, up to 10 mg	<1%	463	$93.45
J2704	Injection, propofol, 10 mg	<1%	110	$92.02
82330		<1%	32	$91.21
88108		<1%	13	$85.26
82310		<1%	72	$66.84
A9503	Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries	<1%	307	$61.38
A9698	Non-radioactive contrast imaging material, not otherwise classified, per study	<1%	2,274	$59.68
G0009	Administration of pneumococcal vaccine	<1%	65	$58.26
G0010	Administration of hepatitis b vaccine	<1%	15	$57.48
90834	Psychotherapy session, about 45 minutes	<1%	13	$52.33
J7120	Ringers lactate infusion, up to 1000 cc	<1%	25	$42.82
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	946	$40.74
A9270	Non-covered item or service	<1%	4,554	$40.01
90792	Psychiatric diagnostic evaluation with medical services	<1%	12	$34.91
87806		<1%	13	$31.38
84630		<1%	15	$30.93
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	<1%	471	$21.82
J8540	Dexamethasone, oral, 0.25 mg	<1%	2,016	$20.92
83605		<1%	16	$15.63
89051		<1%	13	$10.08
84157		<1%	13	$7.20
82945		<1%	13	$7.08
86870		<1%	22	$6.72
85014		<1%	29	$4.93
87186		<1%	27	$3.89
Q0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg	<1%	30	$0.11
Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg	<1%	15	$0.09
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	<1%	6,290	$0.07
C8937	Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)	0%	412	$0.00
J1171	Injection, hydromorphone, 0.1 mg	0%	48	$0.00
C1788	Port, indwelling (implantable)	0%	50	$0.00
J9060	Injection, cisplatin, powder or solution, 10 mg	0%	23	$0.00
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	0%	18	$0.00
87077		0%	15	$0.00
J2003	Injection, lidocaine hydrochloride, 1 mg	0%	271	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDAVIDSON, NANCY (SENIOR VP)